Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Completed · Phase 1

Conditions studied: Hematologic Neoplasms

In brief

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Key facts

Study ID

NCT00595686

Run by

Esanex Inc.

People needed

25

Starts

2008-01-01

Expected to finish

2010-05-01

Last updated by the study team

2012-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18 years old
• Karnofsky performance status > 60
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal and hematological function

You may not qualify if…

• CNS malignancy
• at risk for prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition

Where it is running

• Pfizer Investigational Site — Augusta, Georgia, United States
• Pfizer Investigational Site — Chapel Hill, North Carolina, United States
• Pfizer Investigational Site — Pittsburgh, Pennsylvania, United States
• Pfizer Investigational Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.